New molecule against Glioblastoma (GBM)
The invention is characterized by the discovery of a molecule able to arrest the proliferation and migration of tumoral cells related to solid tumors and especially to the glioblastoma multiforme (GBM). Since today the therapy for this pathology is devoid of effective treatments, the invention is configured as an excellent candidate for the development of a possible drug.
The invention consists in the use of a new chemical compound for the treatment of solid cancerous pathologies in general and with particular reference to glioblastoma multiforme. Indeed, up to now there is no cure for glioblastoma multiforme (GBM). The molecule has shown excellent anti-tumor activity on various types of in vitro tumors, some of which are particularly aggressive and completely devoid of an effective therapy. In particular, the activity of the molecule has proven to be effective on highly proliferating cells, such as those of GBM, whereas in normal nerve cells it didn’t shown any significant toxic effects. The molecule, thanks to its structure, is strongly lipophilic and it easily crosses the blood brain barriers, making it an excellent candidate for the development of a drug for GBM. The mechanism is related to the modulations of the actin-tubulin interactions with their associated binding proteins.
- A candidate for the therapy of solid tumors with particular emphasis to GBM;
- Glioblastoma multiforme (GBM);
- Pancreatic Carcinoma;
- Hepatocellular Carcinoma (HCC);
- Colon Cancer.
- Strong anti-proliferative activity;
- High anti-immigration activity;
- Low toxicity;
- Crossing the blood brain barrier